IL241347B - Methods for obtaining medically effective doses of anti-cd47 agents - Google Patents
Methods for obtaining medically effective doses of anti-cd47 agentsInfo
- Publication number
- IL241347B IL241347B IL241347A IL24134715A IL241347B IL 241347 B IL241347 B IL 241347B IL 241347 A IL241347 A IL 241347A IL 24134715 A IL24134715 A IL 24134715A IL 241347 B IL241347 B IL 241347B
- Authority
- IL
- Israel
- Prior art keywords
- agents
- methods
- therapeutically effective
- effective doses
- achieving therapeutically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800102P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/018743 WO2014149477A1 (en) | 2013-03-15 | 2014-02-26 | Methods for achieving therapeutically effective doses of anti-cd47 agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL241347A0 IL241347A0 (en) | 2015-11-30 |
| IL241347B true IL241347B (en) | 2020-03-31 |
Family
ID=51580621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL241347A IL241347B (en) | 2013-03-15 | 2015-09-09 | Methods for obtaining medically effective doses of anti-cd47 agents |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US9623079B2 (OSRAM) |
| EP (3) | EP2970493B1 (OSRAM) |
| JP (5) | JP6426693B2 (OSRAM) |
| CN (3) | CN112245586A (OSRAM) |
| AU (4) | AU2014238105B2 (OSRAM) |
| CA (1) | CA2903773A1 (OSRAM) |
| DK (1) | DK2970493T3 (OSRAM) |
| ES (1) | ES2728066T3 (OSRAM) |
| IL (1) | IL241347B (OSRAM) |
| PT (1) | PT2970493T (OSRAM) |
| WO (1) | WO2014149477A1 (OSRAM) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3722317B1 (en) | 2008-01-15 | 2024-08-07 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| US11072655B2 (en) * | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| ES2735144T3 (es) | 2008-01-15 | 2019-12-16 | Univ Leland Stanford Junior | Métodos para manipular fagocitosis mediada por CD47 |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| BR112015013431A2 (pt) | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| ES2728066T3 (es) * | 2013-03-15 | 2019-10-22 | Univ Leland Stanford Junior | Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47 |
| ES2765483T3 (es) | 2013-09-18 | 2020-06-09 | Univ Leland Stanford Junior | Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica |
| US10550187B2 (en) * | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
| RU2576614C1 (ru) * | 2015-01-19 | 2016-03-10 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "33 ЦЕНТРАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИСПЫТАТЕЛЬНЫЙ ИНСТИТУТ" Минобороны России | Способ поиска точки с дробным эффектом при определении эффективных доз веществ методом "одной точки" |
| AU2016209268B2 (en) * | 2015-01-21 | 2021-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Macrophages eat cancer cells using their own calreticulin as a guide |
| ES2941387T3 (es) * | 2015-02-27 | 2023-05-22 | Univ Leland Stanford Junior | Terapia de combinación para el tratamiento de la ateroesclerosis |
| US10259859B2 (en) | 2015-08-07 | 2019-04-16 | ALX Oncology Inc. | Constructs having a SIRP-α domain or variant thereof |
| WO2017049251A2 (en) | 2015-09-18 | 2017-03-23 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| US9650441B2 (en) | 2015-09-21 | 2017-05-16 | Erasmus University Medical Center | Anti-CD47 antibodies and methods of use |
| US10344094B2 (en) * | 2015-12-11 | 2019-07-09 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of CD47 and EGFR |
| CN109071676A (zh) * | 2016-01-21 | 2018-12-21 | 小利兰·斯坦福大学托管委员会 | 使用免疫调节剂的组合的癌症治疗 |
| PL3442578T3 (pl) * | 2016-04-15 | 2022-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Sposoby określania i osiągania terapeutycznie skutecznych dawek środków anty-cd47 w leczeniu nowotworów |
| US9957576B2 (en) | 2016-04-21 | 2018-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| PT3448421T (pt) | 2016-04-29 | 2022-01-14 | Univ Leland Stanford Junior | Métodos e composições para a prevenção e tratamento de aderências cirúrgicas |
| US11618784B2 (en) | 2016-07-19 | 2023-04-04 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD47 combination therapy |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| WO2018081448A1 (en) | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| CA3053392A1 (en) | 2017-02-28 | 2018-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Antifibrotic activity of cd47 blockade |
| WO2018165015A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
| CN110831974B (zh) | 2017-06-21 | 2024-05-14 | 小利兰·斯坦福大学托管委员会 | 针对血液恶性肿瘤的cd47靶向疗法的给药参数 |
| EP3661965A4 (en) | 2017-08-02 | 2022-07-13 | Phanes Therapeutics, Inc. | ANTI-CD47 ANTIBODIES AND USES THEREOF |
| EP4194470A1 (en) | 2017-10-18 | 2023-06-14 | Forty Seven, Inc. | Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 |
| US11802153B2 (en) | 2017-10-18 | 2023-10-31 | Forty Seven, Inc. | Anti-CD47 agent-based ovarian cancer therapy |
| US11180552B2 (en) | 2017-12-01 | 2021-11-23 | Seagen Inc. | CD47 antibodies and uses thereof for treating cancer |
| EP4129336B1 (en) * | 2018-02-12 | 2025-05-07 | Forty Seven, LLC | Anti-cd47 agent-based treatment of cd20-positive cancer |
| US11292850B2 (en) | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
| AU2019349651B2 (en) | 2018-09-27 | 2023-12-07 | Celgene Corporation | SIRP alpha binding proteins and methods of use thereof |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| WO2020163692A1 (en) * | 2019-02-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
| KR20220012328A (ko) * | 2019-05-24 | 2022-02-03 | 포티 세븐, 인코포레이티드 | c-kit 및 CD47에 대한 면역요법제의 병용 투여를 위한 요법 |
| CN119700933A (zh) | 2019-05-31 | 2025-03-28 | Alx肿瘤生物技术公司 | 用SIRPαFc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| WO2020247820A1 (en) * | 2019-06-07 | 2020-12-10 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| EP4045083B1 (en) * | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| AU2020410410A1 (en) | 2019-12-17 | 2022-06-09 | Pfizer Inc. | Antibodies specific for CD47, PD-L1, and uses thereof |
| WO2022076928A1 (en) * | 2020-10-09 | 2022-04-14 | Sana Biotechnology, Inc. | METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPα BLOCKADE AGENT |
| WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| CA3227223A1 (en) * | 2021-07-28 | 2023-02-02 | Actinium Pharmaceuticals, Inc. | Combination radioimmunotherapy and cd47 blockade in the treatment of cancer |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| JP2024540448A (ja) | 2021-11-19 | 2024-10-31 | ケーアイエスティー（コリア インスティテュート オブ サイエンス アンド テクノロジー） | 標的細胞への医薬品有効成分の赤血球媒介送達のための治療化合物 |
| WO2023133577A1 (en) * | 2022-01-10 | 2023-07-13 | Kiniksa Pharmaceuticals, Ltd. | Methods of treating or reducing risk of transplant rejection |
| US20250302953A1 (en) | 2022-02-14 | 2025-10-02 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| CN120202222A (zh) | 2022-11-16 | 2025-06-24 | 勃林格殷格翰国际有限公司 | 抗SIRPa抗体的疗效预测性生物标志物 |
| CN120344257A (zh) | 2022-12-09 | 2025-07-18 | 美国辉瑞有限公司 | Cd47阻断剂和抗cd20/抗cd3双特异性抗体组合疗法 |
| KR20250116736A (ko) | 2022-12-09 | 2025-08-01 | 화이자 인코포레이티드 | Cd47 차단제 및 항-bcma/항-cd3 이중특이성 항체 병용 요법 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| US7282556B2 (en) * | 2001-05-15 | 2007-10-16 | Emory University | Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47 |
| US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| WO2007033221A2 (en) * | 2005-09-13 | 2007-03-22 | The General Hospital Corporation | Methods and compositions for inhibition of immune responses |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| JP2011500005A (ja) * | 2007-10-11 | 2011-01-06 | ユニバーシティー ヘルス ネットワーク | ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物 |
| CN101456911A (zh) | 2007-12-12 | 2009-06-17 | 江苏豪森药业股份有限公司 | 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途 |
| ES2735144T3 (es) | 2008-01-15 | 2019-12-16 | Univ Leland Stanford Junior | Métodos para manipular fagocitosis mediada por CD47 |
| EP3722317B1 (en) | 2008-01-15 | 2024-08-07 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| US8758750B2 (en) * | 2009-09-15 | 2014-06-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-CD47 therapy for hematologic cancers |
| WO2011041453A1 (en) * | 2009-09-29 | 2011-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| JP6166177B2 (ja) | 2010-05-14 | 2017-07-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体 |
| SMT202000689T1 (it) * | 2012-01-17 | 2021-01-05 | Univ Leland Stanford Junior | Reagenti per sirp-alfa ad alta affinita' |
| US20140140989A1 (en) * | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| SG10201700160RA (en) * | 2012-02-06 | 2017-03-30 | Inhibrx Lp | Cd47 antibodies and methods of use thereof |
| JP6514103B2 (ja) | 2012-07-06 | 2019-05-15 | ゲンマブ ビー．ブイ． | 三重変異を有する二量体タンパク質 |
| CN105101997B (zh) * | 2013-02-06 | 2018-11-09 | 印希彼有限合伙公司 | 不减少血小板和不减少血红细胞的cd47抗体及其使用方法 |
| ES2728066T3 (es) | 2013-03-15 | 2019-10-22 | Univ Leland Stanford Junior | Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47 |
-
2014
- 2014-02-26 ES ES14768797T patent/ES2728066T3/es active Active
- 2014-02-26 CN CN202010960541.4A patent/CN112245586A/zh active Pending
- 2014-02-26 EP EP14768797.4A patent/EP2970493B1/en active Active
- 2014-02-26 DK DK14768797.4T patent/DK2970493T3/da active
- 2014-02-26 WO PCT/US2014/018743 patent/WO2014149477A1/en not_active Ceased
- 2014-02-26 AU AU2014238105A patent/AU2014238105B2/en active Active
- 2014-02-26 PT PT14768797T patent/PT2970493T/pt unknown
- 2014-02-26 EP EP20201319.9A patent/EP3792285A1/en not_active Ceased
- 2014-02-26 US US14/769,069 patent/US9623079B2/en active Active
- 2014-02-26 CN CN202210327266.1A patent/CN114917336A/zh active Pending
- 2014-02-26 CA CA2903773A patent/CA2903773A1/en active Pending
- 2014-02-26 EP EP19166334.3A patent/EP3536709A1/en active Pending
- 2014-02-26 CN CN201480015159.9A patent/CN105189556A/zh active Pending
- 2014-02-26 JP JP2016500441A patent/JP6426693B2/ja active Active
-
2015
- 2015-09-09 IL IL241347A patent/IL241347B/en active IP Right Grant
-
2017
- 2017-02-02 US US15/423,325 patent/US10301387B2/en active Active
-
2018
- 2018-10-25 JP JP2018201216A patent/JP6704974B2/ja active Active
-
2019
- 2019-01-17 AU AU2019200294A patent/AU2019200294B2/en active Active
- 2019-04-04 US US16/375,238 patent/US11104731B2/en active Active
-
2020
- 2020-05-13 JP JP2020084674A patent/JP7007422B2/ja active Active
- 2020-11-17 AU AU2020270485A patent/AU2020270485B2/en active Active
- 2020-11-23 US US17/102,183 patent/US11136391B2/en active Active
-
2021
- 2021-08-12 US US17/401,046 patent/US12258399B2/en active Active
-
2022
- 2022-01-06 JP JP2022001223A patent/JP7246528B2/ja active Active
- 2022-05-02 US US17/734,949 patent/US11518806B2/en active Active
- 2022-05-02 US US17/734,904 patent/US11603404B2/en active Active
-
2023
- 2023-02-03 US US18/164,252 patent/US12258403B2/en active Active
- 2023-03-14 JP JP2023039709A patent/JP7562736B2/ja active Active
-
2024
- 2024-08-20 AU AU2024210996A patent/AU2024210996A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL241347A0 (en) | Methods for obtaining medically effective doses of anti-cd47 agents | |
| GB201321743D0 (en) | Therapeutic agents | |
| GB201321746D0 (en) | Therapeutic agents | |
| GB201321738D0 (en) | Therapeutic Agents | |
| GB201321736D0 (en) | Therapeutic agents | |
| GB201321729D0 (en) | Therapeutic agents | |
| GB201321733D0 (en) | Therapeutic agents | |
| GB201321728D0 (en) | Therapeutic agents | |
| GB201321730D0 (en) | Therapeutic agents | |
| GB201321739D0 (en) | Therapeutic agents | |
| GB201321741D0 (en) | Therapeutic agents | |
| GB201321740D0 (en) | Therapeutic agents | |
| GB201321732D0 (en) | Therapeutic agents | |
| GB201321734D0 (en) | Therapeutic Agents | |
| GB201321744D0 (en) | Therapeutic agents | |
| GB201321737D0 (en) | Therapeutic Agents | |
| GB201321748D0 (en) | Therapeutic agents | |
| GB201321742D0 (en) | Therapeutic agents | |
| LT3563837T (lt) | Terapija bakteriofagu | |
| GB201321735D0 (en) | Therapeutic Agents | |
| GB201321745D0 (en) | Therapeutic agents | |
| GB201321731D0 (en) | Therapeutic agents | |
| GB201308440D0 (en) | Therapeutic | |
| GB201321749D0 (en) | Therapeutic agents | |
| GB201308466D0 (en) | Improved process for treatment of minewater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |